The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer

Recruiting

• Conditions: Pancreas Cancer; Chemotherapy
• Interventions: Other: Adjuvant chemotherapy

• Registration Number: NCT06208436
• Lead Sponsor: Tianjin Medical University Cancer Institute and Hospital

Brief Summary

This study aimed to evaluate the impact of adjuvant chemotherapy on survival in patients with Stage I pancreatic cancer stratified by pathologic risk factors.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-07
• Study First Submitted: 2023-12-25
• Status Verified: 2024-01
• Study First Submitted QC: 2024-01-06
• Last Update Submitted: 2024-01-06
• Study First Posted: 2024-01-17
• Last Update Posted: 2024-01-17
• Primary Completion: 2024-02-15
• Study Completion: 2024-02-28

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

Patients who underwent surgical resection and were pathologically diagnosed as PDAC between 2010 and 2021.

Exclusion Criteria

Patients with pN1-N2, patients with pT3-T4, patients with distant metastasis, patients who received neoadjuvant therapy, patients with R1 resection, and patients who died due to perioperative mortality within 30 days.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
TMUCIH-PDAC	Adjuvant chemotherapy	Between 2010 and 2021, the data of patients who underwent surgical resection and were pathologically diagnosed as PDAC from Tianjin Medical University Cancer Institute and Hospital (TMUCIH) were collected retrospectively.

Primary Outcome Measures

Name	Time	Method
Recurrence-free survival	January 2010 to February 2023	The period between surgical resection to the date of recurrence.

Secondary Outcome Measures

Name	Time	Method
Overall survival	January 2010 to February 2023	The period between surgical resection to the date of death.

Trial Locations

Locations (1)

Jihui; 🇨🇳 Tianjin, Tianjin, China